Introduction
Myocardial infarction (MI), the leading cause of morbidity and mortality worldwide, 1 occurs when blood supply to a certain region of the heart is totally or partially blocked, with the consequent shortage of oxygen and nutrients supply to cardiac cells, a process called heart ischaemia. In order to ensure the proper replenishment of blood to the deprived areas, affected cells release signals, including growth factors, which stimulate the growth of new vessels. For example, a moderate chronic occlusion of coronaries can result in the development of coronary collateral circulation (CCC), as part of a compensatory strategy to ensure a sufficient blood supply to the ischaemic region. 2, 3 Also healthy physiological cardiac hypertrophy, usually associated with physical exercise, requires an adequate vascular growth that accompanies myocytes enlargement. 4 Although inflammatory mediators and growth factors, such as VEGF and b-FGF, have been implicated in the formation of new vessels in the heart, the biological processes involved in the stimuli-induced angiogenesis remain largely unknown. 3 Angiogenesis, which is the formation of new blood vessels formation from pre-existing vasculature, is a highly controlled mechanism that involves the local breakdown and reorganization of the extracellular matrix (ECM), endothelial cells (ECs) sprouting, migration and adhesion junctions remodelling. 5 It has been shown that signals emitted by cardiomyocytes (CM) impact upon ECs function and modulate angiogenesis. Therefore, a fine-tuned regulation of communication between the different cell types in the heart is vital to ensure a proper vascularization of the heart required to sustain myocardial contraction. 6, 7 Typically, the intercellular communication can occur directly, between adjacent cells, via gap junctions, 8 or indirectly, at long distances, through soluble factors and extracellular vesicles (EVs), including exosomes. These vesicles mediate intercellular communication under normal and pathological conditions by shuttling a wide range of functional lipids, proteins, mRNAs, and microRNAs (miRs). 9 It has been reported that exosomes play an important role in modulating angiogenesis, in different organs, including the heart. 10, 11 For this reason, exosomes have emerged as potential therapeutic agents that can modulate ECs behaviour and elicit an angiogenic response. Indeed, progenitor and stem cellderived exosomes present proangiogenic activity in cardiac ECs, namely in the context of hypoxia and ischaemia, where exosomes can mitigate injury. [12] [13] [14] [15] However, the effect of exosomes secreted by CM subjected to ischaemia on ECs has never been described. In the present study we demonstrate in vitro and in vivo that exosomes produced by CM in ischaemia stimulate cardiac angiogenesis.
Methods
Detailed description of reagents and experimental procedures, cell lines, exosome purification, transmission electron microscopy (TEM), and fluorescence microscopy, nanotracking analysis (NTA), Western blot (WB), miR analysis, in vitro and ex vivo experiments, and animal studies are listed in Supplementary Material.
Exosomes and cell culture
Exosomes were isolated by differential centrifugation. Exosomes size and concentration was measured using NTA. Mouse Cardiac Endothelial Cell (MCEC) and Human Umbilical Vein Endothelial Cells (HUVEC) were incubated with exosomes isolated from H9c2 cells transfected with CD63-GFP, and uptake was determined by confocal microscopy. Primary cultures of cardiomyocytes were obtained from Wistar rat fetus (17-18 days of gestation) following the protocol described in Supplementary Material.
Functional assays
Cell monolayer integrity was assessed by transendothelial electrical resistance (TEER) and permeability assays. Zymography was used to detect MMP activity. The concentration of MMP-9 in isolated exosomes and EC supernatant was determined by ELISA assay. Proliferation was assessed by 5-bromo-2'-deoxyuridine (BrdU) incorporation and Ki67 immunostaining. Cell viability was determined by LIVE/DEAD V R Viability/ Cytotoxicity Kit. Cell migration was determined by the scratch assay. Angiogenic potential was assessed by ECs capillary-like formation on Matrigel. Angiogenic sprouting was evaluated by fibrin gel bead assay. Ex vivo microvessel sprouting from rat thoracic aortas in Matrigel. Chicken embryo chorioallantoic membrane (CAM) model was used to evaluate angiogenesis. In vivo vascular permeability was measured in CAM model by quantification of leakage of Evan's Blue Dye (EBD, Sigma). In vivo angiogenesis was assessed by implantation of matrigel in rat model and further quantification of hemoglobin content.
MI induction and exosome delivery
MI was induced by ligation of the left anterior descending coronary artery and exosomes were delivered into ischaemic region by intramyocardial injections. Blood vessel density was assessed by immunofluorescence detection of CD31, as previously detailed, 16 and Griffonia Simplicifolia Lectin I (GSL-I, Vector Laboratories) as described in Supplementary Material. Transthoracic echocardiography was performed 4 weeks after the surgery using a Vevo 2100 microultrasound platform coupled with a MS400 transducer (both FUJIFILM Visulasonics, Inc.). Four weeks after MI, diastole arrested heart were processed and sectioned according to previously published protocols. 16 In brief, infarctsize assessment was performed by staining paraffin sections according to the Trichrome Masson Stain kit (Sigma-Aldrich) with modifications described in Supplementary Material. Left Ventricle (LV) infarcted area and infarcted midline were measured using the semi-automatic MIQuant Software by a blinded operator and the final result presented as the average percentage throughout the LV. 16 ,17
Statistical analysis
Data were displayed with mean ± SD on a bar or scatter dot plot (each dot represents one animal or independent experiment). Data was analysed with SPSS 22 (IBM) or GraphPad Prism 6 for Windows, version 6.01 (GraphPad Software, Inc.), graphs were assembled in GraphPad Prism 6. P < 0.05 was considered significant.
Results

Characterization of exosomes secreted by H9c2 and rat fetal cardiomyocytes
To evaluate whether ischaemia modulates the profile of vesicles released by CM we isolated, by differential ultracentrifugation, the exosomes secreted by myocardial H9c2 cells cultured either in control (Exo Ct ) or ischaemia-mimetic conditions (Exo Isch ) (hereinafter referred to as ischaemia), after which we used the NTA and TEM ( Figure 1A and B, respectively) to assess the number, size and morphology of the vesicles. The presence of proteins typically enriched in exosomes and absence of calnexin in exosomal extract confirmed that the isolation procedure gave rise to a population of vesicles highly enriched in exosomes ( Figure 1C) . To evaluate if our isolation protocol excludes large protein aggregates or proteins nonspecifically associated with vesicles, we performed an extra purification step using a sucrose. 18 The presence of the exosomal marker CD63 mainly in the sucrose gradient (see Supplementary material online, Figure (SF Figure 1A ).
Stimulation with Exo
Isch induces a transient decrease in TEER and promotes endothelial permeability
To assess the effect of H9c2-derived exosomes on MCEC barrier properties, we evaluated TEER and permeability to dextran in MCEC monolayers. Incubation with Exo Isch lead to a significant TEER reduction between 1 and 12 h post-stimulation that returned to basal levels after 24 h (Figure 2A) Figure 2B and C). Moreover, cells exposed to Exo Ct for 2 h, present smooth lines of continuous staining for VE-cadherin and ZO-1 along cell-cell contacts ( Figure 2D ), suggesting strong adhesion, whereas ECs incubated with Exo Isch had discontinuous and irregular VE-cadherin and ZO-1 distribution at the intercellular junctions. However, after 24 h of incubation, when compared with the results at 2 h, ECs exposed to Exo Ct present a more irregular distribution and decrease staining for VE-cadherin and ZO-1, suggesting a disruption of barrier properties, whereas ECs treated with Exo Isch show less discontinuous borders on the monolayer, accompanied by an increased labelling for VE-cadherin and ZO-1. Western blot analysis revealed that ECs stimulated with Exo Isch have higher levels of ZO-1, VE-cadherin, and Occludin (SF2). Strikingly, the effects described above with cell lines were confirmed in monolayers of primary ECs (HUVEC) stimulated with exosomes released by rFCM. Similarly to MCEC, rFCM_Exo Ct did not affected HUVEC TEER, whereas, rFCM_Exo Isch promoted a significant TEER reduction from 1 to 12 h post-stimulation in primary ECs, values that reverted to basal level after 24 h ( Figure 2E ). Moreover, permeability assay results showed that after 1 h of incubation the permeability to 10 and 70 kDa dextran is higher in cells stimulated with rFCM_Exo Isch than rFCM_Exo Ct ( Figure 2G and H). Also the VE-cadherin staining was higher in HUVEC incubated with rFCM_Exo Isch than rFCM_Exo Ct , supporting the idea that for long periods of incubation ischaemic exosomes strengthen cell-cell adhesions ( Figure 2F ). Altogether these data demonstrate that Exo
Isch cause a transient disruption of the endothelial barrier, with increased paracellular permeability and decreased TEER, after which the barrier properties are re-established or even strengthened.
Exo Isch promote ECM degradation
Previous studies reported that exosomes may carry and deliver active MMPs, namely MMP-2 and -9 that favour angiogenesis. 13, 19 The results presented in Figure 3A and B (gelatine zymography) show that Exo Isch contain higher levels of MMP-9 and MMP-2, in comparison with Exo Ct . In agreement, ELISA data demonstrate that Exo Isch present 2 times more MMP-9 than Exo Ct ( Figure 3C ), suggesting that exosomes released by CM subjected to ischaemia promote the degradation of ECM. Furthermore, we show that Exo Isch enhance the secretion of MMP-2 and MMP-9 by MCEC ( Figure 3D -E, and F). These findings ascribe to exosomes a role in ECM degradation during ischaemia, namely by carrying MMPs released by CM and/or by inducing MMPs secretion by ECs.
Exo Isch promote ECs proliferation and survival upon stress
We subsequently tested whether exosomes released by CM regulate ECs proliferation using two different techniques, Ki67 staining, which is present in all active phases of the cell cycle, and BrdU incorporation.
Both approaches demonstrated that Exo
Isch significantly increased the proliferation of MCEC, compared with Exo Ct ( Figure 3G and H).
Furthermore, we evaluated the impact of Exo Ct and Exo
Isch on the capacity of cells to respond to oxidative stress, often implicated in heart disorders, including myocardial ischaemic syndromes and reperfusionassociated lesions. 20 As shown in Figure 3I , Exo Isch significantly improve ECs viability when subjected to oxidative stress, compared to cells pretreated with Exo Ct , suggesting that Exo Isch can be cardioprotective.
Exo Isch promote ECs migration, capillary-like tube, and sprouting formation
To assess the impact of CM-released exosomes on ECs behaviour and angiogenic potential capacity, we evaluated ECs migration, tube formation and sprouting. The results presented in Figure 4A and Figure 4C and D) .
To evaluate the sprouting of ECs, an important step of the angiogenic process, we used the three-dimensional in vitro angiogenesis system and the ex vivo aortic ring assay. Results represent mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0. Figure 5A ). Pathway enrichment analysis associated up-regulated miRs with pathways related with cell proliferation and differentiation (see Supplementary material online, Table ( ST) 1). GO-term enrichment analysis associated these same targets with genes related to heart development, response to shear stress by fluids and signal transduction (ST2), and genes involved in signal transduction via transcription factors or membrane receptors (ST3). The down-regulated miRs are mainly associated with cancer and cell proliferation pathways (ST4), as well as nucleic acid binding processes (ST5-6). Furthermore, we validated the results of the screening approach in H9c2 and rFCM, concerning the two relatively most abundant miRs present on ischaemic exosomes, miR-143, and miR-222. We confirmed by qPCR that ischaemic exosomes released by H9c2 and rFCM are enriched in miR-143 and miR-222 ( Figure 5B and C, respectively), when compared with exosomes secreted by cells maintained under basal conditions. Importantly, the enrichment in miR-143 and miR-222 as well as the pro-angiogenic properties of Exo Isch are maintained when the exosomal extract is treated with RNase and proteinase K, to degrade free miRNA and dissociate complexes which might otherwise shield RNA, prior to RNA isolation and quantification (SF3A-B and SF4). Moreover, to clarify if miRs were present in exosomes and exclude its presence in protein aggregates, we also quantified miR-143 and miR-222 levels after an extra purification step using the sucrose cushion method. The results demonstrate that the levels of miRNA in the pellet are residual and, more important, in the exosomal fraction recovered in the cushion, the relative enrichment of miR-143 and -222 in Exo Isch compared to Exo Ct was maintained (SF3C). These results support the idea that exosome-mediated response is mediated, at least partially, by miRNA loaded in the vesicles.
Subsequently, we investigated whether these two miRs (miR-143 and miR-222) have an impact on the angiogenic process. The results t-test (Holm-Sidak's); (C, F, G, and H) 2-tailed t-test. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 relative to Exo Ct .
Ischemic exosomes promote heart angiogenesis Figure 5D ) and migration ( Figure 5E) , and promoted the formation of capillary-like structures ( Figure 5F ), and cell sprouting ( Figure 5G) . None of these parameters were significantly altered in MCEC stimulated with miR-222. The increase in intracellular levels of miRNAs -143 and -222 after transfection demonstrated those miRs were taken up by ECs (SF5). Concerning HUVEC, we observed that miR-222 promoted tubulation and sprouting, whereas 
miR-143 had no significant impact in any of these parameters ( Figure 5H-I) . Despite apparently contradictory, these results indicate that these miRs can be, at least partially, responsible for the proangiogenic effect of Exo Isch .
Exo
Isch promote angiogenesis in vivo Figure 6C) . 
Exo Isch promote angiogenesis following MI
To assess the beneficial potential of exosomes produced by ischaemic CM, Exo Ct or Exo Isch were delivered to the myocardium of mice subjected to MI at the onset of injury. Survival rate of animals treated with Exo Isch was higher, which may relate with a protective effect from ischaemia (SF6). One month following MI, mice subjected to Exo isch treatment showed a tendency for an increase in ejection fraction, however due to changes in preload, this does not result in an improvement of systolic cardiac function as assessed by cardiac output (CO) ( Figure 7A and B) , likely owing to the fact that left ventricular chamber of Exo Ct animals was more dilated ( Figure 7C and D and ST7) . Most importantly angiogenesis was enhanced following Exo Isch treatment as shown by higher numbers of CD31 þ cells in the infarcted region ( Figure 7E-F) and of lectin-perfused vessels in the infarction border zone ( Figure 7G-H) of Exo Isch -treated mice. As proangiogenic factors may also promote a reduction on cardiac fibrosis and remodelling after MI, the percentage of collagen deposition was quantified in representative sections of the LV ( Figure 7I ). No differences were detected across groups ( Figure 7J-K) . Altogether, these results are entirely consistent with our hypothesis that exosomes produced by ischaemic CM promote angiogenesis following acute MI thus supporting blood perfusion to the myocardium.
Discussion
A tightly regulated and balanced crosstalk between the different cells that form the heart is vital for cardiac function. It is well established that a Results represent mean ± SD; each dot represents one animal. Experimental groups passed the Shapiro-Wilk normality test (P > 0.05). P value is shown for 2-tailed t-test; whenever equality of variances cannot be assumed (Levene's test P < 0.05, EF), adjusted P value is shown instead.
panoply of paracrine signals secreted by cardiomyocytes, namely growth factors, hormones and genetic material, can modulate vasculature dynamic. For example, physiological cardiac hypertrophy relies on a finetuned interplay between CM and ECs, which promotes the formation of new vessels required to supply the needs of enlarged CM. However, in the context of pathological hypertrophy, the growth of CM mass is not accompanied by a proper angiogenesis process, thus contributing to cardiac dysfunction due to a deficit in blood supply. For this reason, defects in capillary density have been associated with the transition from a compensated to a decompensated cardiac hypertrophy. 4 Although the role of soluble factors-mediated communication between CM and ECs in heart physiopathology is relatively well studied, the involvement of exosomes in this interplay remains largely elusive. In this study we show that exosomes secreted by CM subjected to ischaemia promote angiogenesis, both in vitro and in vivo. Furthermore, we provide strong evidence that miR-222 and miR-143, the relatively most abundant miRs in ischaemic exosomes, account for the angiogenic process.
The involvement of extracellular vesicles in angiogenesis is not without precedents. It was previously shown that exosomes derived from bone marrow-derived mesenchymal stem cells (BMSCs) and induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs) can promote angiogenesis in ischaemia conditions and attenuate tissue injury after an ischaemic insult. 15, 21 Moreover, exosomes released by H9c2 cells in glucose-deprivation induce the transcription of pro-angiogenic genes in ECs. 22 In the present study, we evaluated the effect of ischaemia on exosomes released by two different cell types: a cardiac myoblast cell line (H9c2) and primary cultures of CM. In both cases, we demonstrated that ischaemia affects the size and number of secreted vesicles, as well as their protein and miR content. Importantly, we showed that the exosomes secreted by both cell types are enriched in miR-222 and miR-143.
It is conceivable that ischaemia-induced changes in the miR profile of exosomes reflects a highly selective sorting of miR into exosomes as part of an orchestrated approach to specifically modulate the activity of distant target cells, in order to preserve organ homeostasis. According to our model, as part of a coordinated strategy, CM under ischaemia release miR that sustain the formation and growth of new vessels to replenish blood supply to the deprived area. In accordance, it was previously demonstrated in pulmonary artery ECs that exosome-derived miR-143, or direct transfection of premiR-143, induced cell migration and capillary-like tube formation, and protects against cell death, thus ascribing to this miR pro-angiogenic properties. 23 Concerning miR-222 the results are somehow contradictory. The anti-angiogenic effect of the cluster miR221/miR-222 was demonstrated in diabetes-inducing inhibition of vessel formation and in miR-221/miR-222-transfected HUVEC, where this miR promoted lower migration potential, proliferation and tubule formation capacity. 24, 25 In contrast, studies carried out by Yang et al. showed that conditioned medium from miR-221/miR-222-overexpressing cells induced an increase in the formation of tube-like structures by HUVECs. 26 Additionally, conditioned medium from cells with downregulation of miR-222 (by overexpression of anti-miR-222) was shown to decrease tube-like formation in HUVECs. 27 These apparent conflicting data may derive from the approaches used to evaluate the role of miRs in angiogenesis, i.e. direct transfection vs. conditioned medium. It is likely that the single miR transfection does not entirely mimic the effect of miR-enriched conditioned medium and/or exosomes. Our results show that the angiogenic potential of ischaemic exosomes, enriched in miR-222, and miR-143, is very similar in both MCEC and HUVEC. However, when the impact of each of the two miRs was evaluated individually, the results were slightly different and isolated miRs did not entirely recapitulate the effect of exosomes. While the miR-222 presents a pro-angiogenic potential in HUVEC (with no significant effect on MCEC), the miR-143 promotes angiogenesis only in MCEC. This is not surprisingly, since the approach using single miR does not take into consideration other biomolecules present in exosomes, namely other miRs, lipids and proteins, the profile of whose can change with ischaemia and can differentially affect angiogenesis. Indeed, when stimulated with exosomes the cells are exposed to a myriad of factors acting simultaneously, leading to a global comprehensive effect. However, when using a single miR a more complex and orchestrated response involving a multitude of effects elicited by the combination of various molecules present at exosomes is lost. The apparent different effect of miR-222 and miR-143 in two distinct ECs can be due to the diverse roles these miRs play either in large vessels or microvasculature, HUVEC and MCEC, respectively. In addition to the miR content, it is likely that the effect of exosomes on ECs depends on the protein content. For example, changes in the profile of proteins on the surface of exosomes can modulate the interaction of the vesicles with the acceptor cells, thus dictating the final effect. It is plausible that the mode of exosome docking at cell surface might not only mediate the selective access of exosomes into the cytoplasm of ECs but also trigger signalling cascades that would culminate in angiogenesis. Besides activation of signalling pathways, it is plausible that a decrease in the levels of short-lived proteins, with important role in angiogenesis, after a few hours of treatment with exosomes or miRNAs, account for the rapid effect of exosomes. It is worth noting that Connexin43 (Cx43), that is known to undergo a profound remodelling upon heart ischaemia and reperfusion, can facilitate the release of exosomal content into target cells. 28 Hence, it is conceivable that ischaemiamediated changes in the content of Cx43 in exosomes determine the interaction and the effect on target cells. It was previously shown that cardiomyocyte progenitor cells (CMPCs)-derived exosomes contain several MMPs, suggesting that exosomes themselves are able to breakdown the ECM or to activate proactive MMPs. 13 In accordance, we observed that Exo Isch not only carry MMPs, namely MMP-2 and -9, capable of degrading matrix but also have the capacity to promote the production and release of MMPs by ECs. Additionally, we show that Exo Isch start by inducing a transient disruption of endothelial barrier properties followed by the strengthening of interendothelial junctions. Consistent with the cell-based approaches, in vivo studies, using the CAM and Matrigel plug models, demonstrate that Exo Isch promote an increase in the formation of new functional nonleaky vessels. Previous studies have demonstrated that exosomes derived from stem and progenitor cells injected intramyocardially reduce myocardial ischaemia/reperfusion injury through proangiogenic effects. 29, 30 However, the effect of ischaemic exosomes on heart angiogenesis has never been addressed. Our data show that the intramyocardial delivery of ischaemic exosomes increases the frequency of perfused vessels in the infarct border zone as well as the number of CD31 þ cells in the ischaemic region when compared to the control exosomestreated group. Of note, although in physiological conditions, myocardial CD31 þ cells are ECs, in an injury scenario it is conceivable that this compartment may also include bone marrow-derived CD45 þ CD31 þ cells, which have been previously associated with proangiogenic properties. 31 significant changes in either infarct size and cardiac function were observed, possibly because the amount of revascularization elicited by the delivered exosome dosage might not have been enough to halt cardiac remodelling alone. Nevertheless, these results strongly support our main conclusion that exosomes secreted by CM subjected to ischaemia promote cardiac angiogenesis following MI. Despite the biological impact of our results, the fact that the amount of exosomes used likely exceeds that found in 'pathophysiological' conditions in vivo might constitute a drawback in terms of clinical significance. Moreover, in our study we used the LAD permanent occlusion MI model, rather than an ischaemia/ reperfusion model that could be more clinical relevant, since our main purpose was just to create more favourable experimental conditions to assess the formation of new vessels in the heart (the high vessel density of non-infarcted myocardium would most likely mask the evaluation of the pro-angiogenic potential of exosomes).
To the best of our knowledge, this is the first study showing that exosomes released by ischaemic CM promote angiogenesis, which can constitute a significant contribution to elucidate the mechanisms underlying the growth of new vessels in the heart. Although the determinants of development of CCC remain controversial, it has been associated with fluid shear stress on ECs and the attraction of monocytes. However, it is conceivable that CM subjected to a chronic and prolonged stress insult produce exosomes that sustain the growth of new vessels underlying CCC. It can be also speculated that the growth of new vessels implicated in healthy hypertrophy is modulated by exosomes released by hypertrophic cardiomyocytes, namely the miR-222 and miR-143, known to promote physiological cardiac hypertrophy. 33 Overall, our study can open new avenues towards the use of exosomes as cell-free therapeutic agent for the induction of local neovascularization after MI.
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